Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.33 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31758157 | 0.64 | USP2 (0.39) | CYP3A4CYP2C19USP2HSD17B10CYP2C9 | |
| SCHEMBL30421257 | 0.63 | CYP2C19 (0.50) | CYP3A4CYP2C19USP2HSD17B10CHRNB2 | |
| SCHEMBL3621172 | 0.63 | BRD4 (0.38) | CYP3A4CYP2C19USP2HSD17B10CHRNB2 | |
| SCHEMBL25839457 | 0.62 | USP2 (0.41) | CYP3A4CYP2C19USP2HSD17B10CYP2C9 | |
| SCHEMBL13515908 | 0.61 | USP2 (0.43) | CYP3A4CYP2C19USP2HSD17B10CHRNB2 | |
| Ethylene SCHEMBL10652976 | 0.61 | CHRNB2 (0.40) | CYP3A4CYP2C19CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL15014465 | 0.60 | CYP2C9 (0.42) | CYP3A4CYP2C19USP2HSD17B10CHRNB2 | |
| SCHEMBL31278727 | 0.59 | USP2 (0.39) | CYP3A4CYP2C19USP2HSD17B10CHRNB2 | |
| SCHEMBL19882914 | 0.59 | USP2 (0.42) | CYP3A4CYP2C19USP2HSD17B10CHRNB2 | |
| SCHEMBL3231020 | 0.58 | CHRNB2 (0.53) | CYP3A4CYP2C19USP2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008789-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2024259169-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008789-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | CYP3A4 3694/4885CYP2C19 1965/4885USP2 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.